| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
4 companies
Daly James M is a Director at HALOZYME THERAPEUTICS, INC. with holdings across 4 companies. Recent SEC Form 4 filings include 0 buys and 27 sells.
Estimated insider holdings value: $2.9M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2025 | ACAD Acadia Pharmaceuticals Inc | Director | Sell | 30,000 | $22.37 | $670,983.00 | -88.1% | +4.6% | - | |
| Feb 27, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE | 15,470 | $347.45 | $5,375,125.55 | -41.8% | -19.3% | +28.8% | |
| Apr 2, 2024 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE | 32,489 | $252.97 | $8,218,630.32 | -32.3% | +14.2% | +36.9% | |
| Aug 14, 2023 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 20,000 | $43.73 | $874,520.00 | -28.2% | -14.5% | +27.7% | |
| Nov 25, 2020 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 10,363 | $40.41 | $418,799.92 | -33.0% | - | - | |
| Aug 13, 2020 | HALO Halozyme Therapeutics, Inc. | Director | Sell | 34,337 | $29.12 | $999,893.44 | -52.3% | - | - | |
| May 11, 2020 | ACAD Acadia Pharmaceuticals Inc | Director | Sale+OE | 26,250 | $51.13 | $1,342,178.25 | -100% | - | - | |
| Sep 9, 2019 | ACAD Acadia Pharmaceuticals Inc | Director | Sale+OE | 30,000 | $37.80 | $1,133,860.08 | -98.7% | - | - |